sandoz image

Novartis invests further into Poland

pharmafile | May 11, 2015 | News story | Manufacturing and Production, Sales and Marketing Novartis, Poland, Sandoz, manufacturing, packaging 

Sandoz the generics division of Novartis has opened a large packaging centre in Stryków in Poland.

Valued at 171 million PLN the move makes it one of the largest investment projects into the Polish pharma sector completed in recent years. 

In expanding its existing plant in Stryków it has generated 90 new jobs to date, and Sandoz has plans to add an additional 40 posts shortly. 

Ard van der Meij who is the president of the board at Sandoz Poland, says: “This investment will greatly facilitate the manufacturing and packaging process, as we will be able to pack around four billion of manufactured tablets, without the need to send them to external packaging facilities”. 

The drug manufacturing plant in Stryków is one of the biggest Sandoz production facilities. The five billion tablets it manufactures every year in Stryków are exported to around 60 countries worldwide. 

The facility produces painkillers, anti-inflammatory medicines (ketoprofen), diabetes medicines (metformin, glimepiride), as well as medications for vascular hypertension (ramipril, torasemide).

As part of the growing Sandoz production and logistics site in Stryków, a modern packaging and warehousing center has been added to the existing manufacturing plant.

The ribbon-cutting ceremony was led by Polish deputy prime minister Janusz Piechociński, who underlined the importance of the Sandoz investment for the development of the country’s economy, and noted that Poland plays a significant role in the worldwide pharma industry. 

van der Meij adds: “Poland plays a vital role in our company’s growth strategy. This investment will increase the capacity of the plant and, simultaneously, reduce costs.

“Our decision to expand the Stryków site was motivated by two key considerations: the excellent location of the site, right at the heart of Europe, and the accessibility to highly qualified personnel.” 

The plant is expected to reach full production by the end of this year. 

Brett Wells

Related Content


Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing …

ViroCell and GOSH gain MHRA manufacturing approval

ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great …

Astellas plans to invest over €330m in new facility in Ireland

Astellas Pharma has announced that it is preparing to submit a planning application to build …

Latest content